ClinicalTrials.gg
RecruitingNCT04219254Updated Jun 25, 2026

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Phase 1/2 interventional study of BI1206 in Solid Tumor, Adult, sponsored by BioInvent International AB. Recruiting at 26 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by BioInvent International AB · Phase 1/2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
197
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Read the detailed description

This is a Phase 1/2a, multicenter, dose-finding, consecutive-cohort, open-label trial of BI-1206 in combination with pembrolizumab in subjects with advanced solid tumors.

The trial will consist of 2 main parts:

Phase 1 with 2 different sets of cohorts assessing IV or SC dosing, with dose escalation of BI-1206 and selection of the RP2D of IV dosing (ivRP2D) and the RP2D of SC dosing (scRP2D).

Phase 2a with 2 parts: a signal seeking and a dose optimization part. In the signal seeking part, subjects with uveal melanoma and Non-Small Cellular Lung Cancer (NSCLC) will be treated with Pembrolizumab intravenously and BI-1206 at the scRP2D subcutaneously. In the dose optimization part, subjects with NSCLC will be randomized into one of 3 expansion arms and treated with pembrolizumab and BI-1206 at the scRP2D.

Subjects will initially receive 3 cycles of therapy with pembrolizumab in combination with BI-1206, either IV or SC.

Subjects who show clinical benefit (CR, PR, or SD) at the Week 9 Visit may continue on combination therapy (pembrolizumab/BI-1206). Starting at Week 10, these subjects will receive additional cycles of pembrolizumab and BI-1206 every 3 weeks for up to 32 additional cycles or up to 2 years from their first dose of BI-1206 therapy or until progression.

Note: The study is only open for enrolling subjects into the phase 2a part.

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

BioInvent International AB is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is willing and able to provide written for the trial.
  • Is ≥18 years of age on day of signing informed consent.
  • Phase I only: Has a confirmed advanced solid tumor. Subjects must have received at least 2 doses of an approved /L1 mAb, and have documented progression on or within 12 weeks from the last dose of anti-PD-1/L1 mAb.
  • For patients with NSCLC (phase 2A SC cohorts):

Have a histologically confirmed diagnosis of advanced or NSCLC and not have an EGFR sensitizing (activating) mutation or an ALK translocation.

Have a PD-L1 positive (TPS≥50%) tumor as determined by IHC at a local laboratory.

Have not received prior systemic immunotherapy or chemotherapy treatment for their advanced/metastatic NSCLC.

Have provided formalin-fixed tumor tissue sample from a of a tumor lesion either at the time of or after the diagnosis of advanced or metastatic disease has been made and from a lesion not previously irradiated to perform biomarker analysis.

  • For patients with uveal melanoma (phase 2A SC cohort): Have a histologically confirmed diagnosis of advanced or metastatic uveal melanoma

Have a PD-L1 positive (TPS≥1%) tumor as determined by IHC at a local laboratory.

Have not received prior systemic immunotherapy or chemotherapy treatment for their advanced/metastatic uveal melanoma. Subjects who have received previous treatment with tebentafusp and/or liver directed therapy are allowed.

Have provided formalin-fixed tumor tissue sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of advanced or metastatic disease has been made and from a site not previously irradiated to perform biomarker analysis.

  • Phase I only: Is intolerant of, refuses, or is not eligible for standard antineoplastic therapy.
  • Has at least 1 lesion as defined by (RECIST v1.1)
  • Phase IIa only: Is willing to provide an archival tumor tissue sample or newly obtained [core, incisional, OR excisional] biopsy of a tumor lesion not previously irradiated.
  • Is able to safely undergo a baseline tumor tissue biopsy prior to first dose of BI-1206.
  • Has a of ≥12 weeks.
  • Has an performance status of 0-1.
  • Has adequate organ function as confirmed by laboratory values listed in the main body of the protocol
  • Phase IIa only: Participants who are positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrolment
  • Phase IIa only: Participants with history of infection are eligible if HCV viral load is undetectable at Screening
  • Phase IIa only: Has adequate hematological and biochemical indices as listed in the main body of the protocol

Exclusion criteria

Exclusion Criteria:

  • Needs doses of prednisolone >10 mg daily (or equipotent doses of other ) while on the study, other than as premedication.
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  • Has known or suspected to pembrolizumab or BI-1206 or any of their .
  • Has cardiac or renal amyloid light-chain (AL) amyloidosis.
  • Has received radiotherapy within 2 weeks of the first dose of BI-1206.
  • Has not recovered from AEs to at least Grade 1 by v5.0 (or higher) due to prior anticancer therapies• Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active, known or suspected disease.
  • Is a female subject and has the ability to become pregnant (or already pregnant or lactating/breastfeeding)
  • Is a male subject with partner(s) of (unless he agrees to use a barrier method of during the study and for 12 months after completing treatment)
  • Has had major surgery from which the subject has not yet recovered Is at high medical risk because of non-malignant systemic disease, including severe active infections on treatment with antibiotics, antifungals, or antivirals
  • Has presence of chronic .
  • Has had an allogenic tissue/solid organ transplant.
  • Has a known history of infection
  • Has a history of active tuberculosis (Bacillus tuberculosis)
  • Has received a within 30 days before the first dose of study treatment
  • Has uncontrolled or significant cardiovascular disease as listed in the main body of the protocol
  • Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or lead to participation not being in the best interest of the subject, in the opinion of the treating Investigator.
  • Is participating or planning to participate in another interventional clinical study or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study drug
  • Has a known additional of another type, with the exception of adequately treated cone-biopsied carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) and basal or squamous cell carcinoma of the skin
  • Has a diagnosis of primary or acquired immunodeficiency disorder or has taken any other form of therapy within 7 days prior to the first dose of study drug.
  • Is unable to attend the study site to receive the study treatment

Additional exclusion criteria are described in the protocol.

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
197 participants (estimated)

Study arms

  • Experimental
    BI-1206 + Pembrolizumab 25mg/mL (MK-3475)

    BI-1206 administrated either IV or SC + Pembrolizumab 200mg administered IV every third week as a fixed dose will be used.

    Drug: BI1206

Interventions

  • DrugBI1206

    BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa. The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase

    Also known as: Pembrolizumab 25mg/mL (MK-3475)

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Documentation of AEs and SAEs, clinically significant laboratory parameters, and physical findings, as well as their causality to BI-1206 and/or pembrolizumab administration

    Assess the safety and tolerability profile of increasing doses of BI-1206, administered IV or SC, in combination with pembrolizumab in subjects with advanced solid tumors

    Time frame: Up to 2 year

  2. DLT occurrence; determination of signal-seeking dose, the MTD or maximum administered dose of BI-1206 in Phase 1, based on the mTPI-2 design

    In Phase 1, identify DLTs, determine the MTD, and select a signal-seeking Phase 2a dose of BI-1206 given via IV infusion or SC injection in combination with pembrolizumab (administered at the standard dose of 200 mg every 3 weeks) to subjects with advanced solid tumors who are experiencing disease progression and have been previously treated with anti-PD-1 or anti- PD-L1 antibodies

    Time frame: During the 42-day treatment period on induction therapy

Secondary outcomes

  1. Determination of standard PK parameters (i.e., AUC, Cmax, Tmax, and terminal half-life [t½]) for BI-1206

    Study the PK profile of BI-1206 administered IV or SC in combination with pembrolizumab in subjects with advanced solid tumors

    Time frame: Up to 2 year

  2. Measurement of ADA response to BI-1206.

    Assess the immunogenicity of BI-1206, administered IV or SC, in subjects with advanced solid tumors, when given in combination with pembrolizumab.

    Time frame: Up to 2 year

  3. Measurement of CD32b receptor occupancy on B cells.

    Evaluate the effect of BI-1206 IV or SC when administered in combination with pembrolizumab on CD32b receptor occupancy on B cells in subjects with advanced solid tumors.

    Time frame: Up to 2 year

Other outcomes

  1. Assessment of best disease responses according to Immunological Response Evaluation Criteria in Solid Tumors (iRECIST).

    Assess possible anti-tumor activity of BI-1206 administered IV or SC in combination with pembrolizumab, 8 weeks after first dose of BI-1206 (i.e., the Week 9 Visit), including follow-up confirmation for progressive disease (PD), in subjects with advanced solid tumors

    Time frame: 8 weeks after first dose BI1206 and every 9 weeks for subjects who continue on therapy

  2. Measurement of progression free survival.

    Assess the duration of clinical response to BI-1206 administered IV or SC in combination with pembrolizumab.

    Time frame: Up to 2 year

  3. Measurement of duration of objective response and objective response rate

    Duration of response: Time-to-event estimates will be generated using the Kaplan-Meier method. Objective response rate: ORR is defined as the percentage of subjects who achieved CR or PR.

    Time frame: Up to 2 year

  4. Measurement of peripheral blood B-lymphocyte counts

    Evaluate the effect of BI-1206 administered in combination with pembrolizumab on the depletion of peripheral blood B-lymphocytes in subjects with advanced solid tumors

    Time frame: Up to 2 year

  5. Measurement of expression levels of immunological markers and/or other biomarkers in tissue biopsies and blood

    Study the expression levels of immunological markers and/or other biomarkers of cohort specific disease(s) and markers of treatment response in the tumor and/or peripheral blood and study the potential correlation of levels of expression with clinical responses

    Time frame: Up to 2 year

  6. Measurement of BI-1206 and pembrolizumab presence in tissue biopsies using immunohistochemistry

    Evaluate the tumor penetrance of BI-1206 and pembrolizumab. Only applicable in Phase 1.

    Time frame: Up to 2 year

  7. Determination of Fcγ receptor isoforms using nucleotide-based assays on genetic material extracted from whole blood and/or tissue

    Investigate the genetic background of participants with respect to FcγR isoforms and explore a potential correlation of the genetic background with clinical responses

    Time frame: Up to 2 year

  8. Measurement of serum cytokine levels and/or soluble CD32b.

    Study the potential cause of infusion related reaction (IRR), such as cytokine release and/or soluble CD32b

    Time frame: Up to 2 years

07

Study locations

16 of 26 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All information concerning the product as well as any matter concerning the operation of the Sponsor, such as clinical indications for the drug, its formula, methods of manufacture and other scientific data relating to it, that have been provided by the Sponsor and are unpublished, are confidential and must remain the sole property of the Sponsor. The Investigator will agree to use the information only for the purposes of carrying out this studytrial and for no other purpose unless prior written permission from the Sponsor is obtained.

Supporting information: Study protocol

Time frame: Within one year from end of study

Access criteria: Paper copy of CSR

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for Nov 2027, 89 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Jan 7, 2020
StartActual
Jun 29, 2020
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04219254
Lead sponsor
BioInvent International AB
Responsible party
Sponsor
First posted
Jan 7, 2020
Start date
Jun 29, 2020
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Philipp Zimmermann, Dr. rer. nat.
Contact
philipp.zimmermann@bioinvent.com
+46735504521
Andres McAllister, PhD
Contact
andres.mcallister@bioinvent.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI-1206

Start the discussion